CABIBBO, Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 7.149
EU - Europa 2.633
AS - Asia 1.256
AF - Africa 50
OC - Oceania 8
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.106
Nazione #
US - Stati Uniti d'America 7.138
IT - Italia 1.013
CN - Cina 602
SG - Singapore 521
FI - Finlandia 387
DE - Germania 314
UA - Ucraina 248
IE - Irlanda 168
GB - Regno Unito 154
SE - Svezia 74
RU - Federazione Russa 68
RO - Romania 53
CI - Costa d'Avorio 45
FR - Francia 43
IN - India 40
BE - Belgio 32
NL - Olanda 22
KR - Corea 21
HK - Hong Kong 14
IR - Iran 13
CA - Canada 11
CH - Svizzera 10
TR - Turchia 9
ES - Italia 8
PL - Polonia 8
BG - Bulgaria 6
JP - Giappone 6
AU - Australia 5
TW - Taiwan 5
AT - Austria 4
DK - Danimarca 4
EG - Egitto 4
EU - Europa 4
LB - Libano 4
PK - Pakistan 4
TH - Thailandia 4
BR - Brasile 3
CZ - Repubblica Ceca 3
NZ - Nuova Zelanda 3
VN - Vietnam 3
AF - Afghanistan, Repubblica islamica di 2
GR - Grecia 2
LT - Lituania 2
MD - Moldavia 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
GH - Ghana 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
LV - Lettonia 1
ME - Montenegro 1
PE - Perù 1
PH - Filippine 1
PY - Paraguay 1
RS - Serbia 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 11.106
Città #
Fairfield 1.136
Chandler 722
Ashburn 626
Woodbridge 556
Singapore 446
Houston 427
Seattle 418
Wilmington 403
Cambridge 377
Ann Arbor 304
Medford 191
Palermo 174
Dublin 168
Altamura 161
Jacksonville 137
Princeton 116
Lawrence 109
Nanjing 98
Des Moines 78
New York 74
Santa Clara 74
San Diego 65
Beijing 62
Jinan 57
Boardman 50
Milan 49
Abidjan 45
Dearborn 45
Venice 45
Ludwigshafen am Rhein 44
Shenyang 44
London 41
Tulsa 37
Hebei 33
Brussels 32
Nanchang 31
Rome 31
Zhengzhou 31
Changsha 26
Helsinki 25
Tianjin 23
Ningbo 22
Bremen 20
Kumar 20
Saint Petersburg 20
Columbus 19
Jiaxing 19
Hangzhou 17
Krefeld 15
Pune 15
Lappeenranta 14
Seongnam 14
Guangzhou 13
Verona 13
Orange 12
Redwood City 12
San Paolo di Civitate 12
Dallas 11
Falls Church 11
Los Angeles 11
Central 10
Tehran 10
Pisa 9
Taizhou 9
Düsseldorf 8
Norwalk 8
Phoenix 8
Redmond 8
Tappahannock 8
Paris 7
Toronto 7
Auburn Hills 6
Cagliari 6
Detroit 6
Forest City 6
Indiana 6
Kilburn 6
Munich 6
Shenzhen 6
Taiyuan 6
Amsterdam 5
Bari 5
Bologna 5
Catania 5
Chicago 5
Edinburgh 5
Haikou 5
Hanover 5
Izmir 5
Lanzhou 5
Messina 5
Naples 5
Napoli 5
Southwark 5
Tokyo 5
Vicopisano 5
Appignano 4
Arezzo 4
Falconara Marittima 4
Hounslow 4
Totale 8.143
Nome #
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 176
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 170
Treatment of hepatocellular carcinoma: present and future. 169
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 168
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. 167
The cheating liver: imaging of focal steatosis and fatty sparing 167
Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid 158
Computed tomography of bowel obstruction: Tricks of the trade 152
The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. 151
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 151
Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? 150
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 150
Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma 149
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 147
Causes of and prevention strategies for hepatocellular carcinoma. 147
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 144
Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device-Initial observations. 142
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 142
Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. 141
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 140
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 138
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 137
Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist 136
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. 135
Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing 133
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 132
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. 131
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 131
Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in post-operative Crohn's disease 130
Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance 129
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 129
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 129
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. 128
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. 127
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 127
Hyperferritinemia is a risk factor for steatosis in chronic liver disease. 127
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. 127
Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. results from a prospective study 126
Imaging appearance of treated hepatocellular carcinoma. 123
Assessment of treatment response in hepatocellular carcinoma: a review of literature 123
Treatment of hepatitis C: critical appraisal of the evidence 121
Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. 120
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study 120
Mortality in patients with hepatocellular carcinoma predicted by six scoring: none is the winner 116
"Should cirrhosis change our attitude towards treating non-hepatic cancer?" 116
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 116
L'impiego del Tachosil in chirurgia epatica 114
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 114
Multimodal approaches to the treatment of hepatocellular carcinoma. 113
Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation - authors' reply 110
Prognostic scores for hepatocellular carcinoma: none is the winner. 109
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 109
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. 108
Minor hepatic resection using heat coagulative necrosis. 107
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? 105
Gadoxetic acid-enhanced MRI of transient hepatic enhancement differences: Another cause of hypointense observation on hepatobiliary phase 105
Update on new approaches in the management of hepatocellular carcinoma. 103
Sorafenib for hepatocellular carcinoma: From randomized controlled trials to clinical practice 103
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 102
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. 102
Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease 101
Sicurezza ed efficacia della chemioembolizzazione arteriosa transcatetere nel trattamento dei pazienti con epatocarcinoma: studio triennale di 75 pazienti italiani 100
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 100
Extrahepatic spread of hepatocellular carcinoma 95
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib 89
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 88
Radio-frequency thermal ablation (RFTA) of small hepatocellular carcinoma in patients with cirrhosis. Experience at a single tertiary referral center 83
Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure 78
The changing scenario of hepatocellular carcinoma in Italy: an update 77
L'impiego del Tissue-Link FB3.0 floating ball nelle resezioni epatiche 76
Hyperintense nodule-in-nodule on hepatobiliary phase arising within hypovascular hypointense nodule: Outcome and rate of hypervascular transformation 73
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis 71
A rs4374383 Single Nucleotide Polymorphisms of MERTK gene is linked to a higher likelihood of hepatocellular carcinoma in patients with HCV cirrhosis 68
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 68
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? 65
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database 63
Epidemiology, risk factors and surveillance of hepatocellular carcinoma 63
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 62
Seeding after radiofrequency thermal ablation of hepatocellular carcinoma in cirrhosis: a prospective study 61
Reply to: Sorafenib in clinical practice: Evidence-based use or abuse? 56
Reply 55
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 55
NATURAL HISTORY OF HEPATOCELLULAR CARCINOMA AND EFFECTS OF TREATMENTS 54
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials 54
Systemic therapies for hepatocellular carcinoma: The present and the future 54
Chemoprevention for hepatocellular carcinoma: the role of statins 53
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors 52
MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine 52
Antiviral therapy in the palliative setting of HCC (BCLC-B and -C) 52
HBV virological suppression: Still not enough to save from hepatocellular carcinoma. A case report on a 15-year, real-life story 50
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 50
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 49
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort 49
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 48
Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e Interventistica (SIRM), Società Italiana di Chirurgia (SIC), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part II - Solid lesions 46
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 46
Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter 46
Recurrence of hepatocellular carcinoma after liver transplantation: An update 43
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 43
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 42
Totale 10.422
Categoria #
all - tutte 56.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.021


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.611 0 0 0 0 0 298 276 183 293 146 323 92
2020/20211.432 82 119 115 96 124 92 72 103 176 176 140 137
2021/20221.463 107 226 32 36 31 61 57 110 211 134 199 259
2022/20232.251 205 446 39 218 242 297 100 156 373 51 93 31
2023/20241.015 44 140 49 69 71 280 105 60 24 26 42 105
2024/20251.129 85 183 358 283 93 127 0 0 0 0 0 0
Totale 11.903